X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
48
PharmaCompass offers a list of Duloxetine API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Duloxetine manufacturer or Duloxetine supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Duloxetine manufacturer or Duloxetine supplier.
PharmaCompass also assists you with knowing the Duloxetine API Price utilized in the formulation of products. Duloxetine API Price is not always fixed or binding as the Duloxetine Price is obtained through a variety of data sources. The Duloxetine Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Cymbalta manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Cymbalta, including repackagers and relabelers. The FDA regulates Cymbalta manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Cymbalta API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Cymbalta manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Cymbalta supplier is an individual or a company that provides Cymbalta active pharmaceutical ingredient (API) or Cymbalta finished formulations upon request. The Cymbalta suppliers may include Cymbalta API manufacturers, exporters, distributors and traders.
click here to find a list of Cymbalta suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Cymbalta DMF (Drug Master File) is a document detailing the whole manufacturing process of Cymbalta active pharmaceutical ingredient (API) in detail. Different forms of Cymbalta DMFs exist exist since differing nations have different regulations, such as Cymbalta USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Cymbalta DMF submitted to regulatory agencies in the US is known as a USDMF. Cymbalta USDMF includes data on Cymbalta's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Cymbalta USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Cymbalta suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Cymbalta Drug Master File in Japan (Cymbalta JDMF) empowers Cymbalta API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Cymbalta JDMF during the approval evaluation for pharmaceutical products. At the time of Cymbalta JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Cymbalta suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Cymbalta Drug Master File in Korea (Cymbalta KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Cymbalta. The MFDS reviews the Cymbalta KDMF as part of the drug registration process and uses the information provided in the Cymbalta KDMF to evaluate the safety and efficacy of the drug.
After submitting a Cymbalta KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Cymbalta API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Cymbalta suppliers with KDMF on PharmaCompass.
A Cymbalta CEP of the European Pharmacopoeia monograph is often referred to as a Cymbalta Certificate of Suitability (COS). The purpose of a Cymbalta CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Cymbalta EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Cymbalta to their clients by showing that a Cymbalta CEP has been issued for it. The manufacturer submits a Cymbalta CEP (COS) as part of the market authorization procedure, and it takes on the role of a Cymbalta CEP holder for the record. Additionally, the data presented in the Cymbalta CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Cymbalta DMF.
A Cymbalta CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Cymbalta CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Cymbalta suppliers with CEP (COS) on PharmaCompass.
A Cymbalta written confirmation (Cymbalta WC) is an official document issued by a regulatory agency to a Cymbalta manufacturer, verifying that the manufacturing facility of a Cymbalta active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Cymbalta APIs or Cymbalta finished pharmaceutical products to another nation, regulatory agencies frequently require a Cymbalta WC (written confirmation) as part of the regulatory process.
click here to find a list of Cymbalta suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Cymbalta as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Cymbalta API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Cymbalta as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Cymbalta and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Cymbalta NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Cymbalta suppliers with NDC on PharmaCompass.
Cymbalta Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Cymbalta GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Cymbalta GMP manufacturer or Cymbalta GMP API supplier for your needs.
A Cymbalta CoA (Certificate of Analysis) is a formal document that attests to Cymbalta's compliance with Cymbalta specifications and serves as a tool for batch-level quality control.
Cymbalta CoA mostly includes findings from lab analyses of a specific batch. For each Cymbalta CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Cymbalta may be tested according to a variety of international standards, such as European Pharmacopoeia (Cymbalta EP), Cymbalta JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Cymbalta USP).
Market Place
